OSAKA, Japan and CAMBRIDGE, Massachusetts, January 30, 2025 – Takeda (TSE:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Mrs. Kim will be proposed as a candidate for election to the Board at Takeda’s Annual General Shareholders Meeting held in June 2026. Mr. Weber will not hold a Board seat after retiring from Takeda.  

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026  | Takeda Pharmaceuticals

**OSAKA, Japan and CAMBRIDGE, Massachusetts, January 30, 2025** – Takeda ([TSE:4502/NYSE:TAK](https://www.takeda.com/investors/)) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. For details, please see [here](https://assets-dam.takeda.com/image/upload/v1738218882/Global/News_Room/Press_Release/2024/successor-ceo/Julie_Kim_will_Succeed_Christophe_Weber_as_CEO_of_Takeda_in_June_2026.pdf).

Article Title

# Section Title

Cancel

Links to sites outside of takeda.com are provided as a resource to the audiences. Please note that Takeda is not responsible or liable for any third-party website and the website may not be appropriate for all audiences. 

To stay on the current website, select “Cancel”
